Pacific Biosciences of California, Inc.

As of June 30, 2026, Pacific Biosciences of California, Inc. carries a market capitalization of 471.81M, placing it among publicly traded companies globally. Its enterprise value stands at 882.55M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Pacific Biosciences of California, Inc.'s next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Pacific Biosciences of California, Inc. has 310.81M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 3.32, and the price-to-book ratio stands at -16.23.

These figures are as of June 30, 2026. The EV/Sales ratio of 6.33 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 882.55M versus a market cap of 471.81M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Pacific Biosciences of California, Inc. maintains a current ratio of 4.92, meaning it holds 4.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -2,126.06, indicating conservative leverage, while an interest coverage ratio of -15.75 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -16.66, reflecting losses generated across the asset base. The company generates approximately 274,699.32 in revenue per employee across its workforce of 507.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.76 indicates how many times Pacific Biosciences of California, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Pacific Biosciences of California, Inc. recorded 723,873.10 in income tax expense. The company reported a pretax loss of -114.28M and -115.00M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

These figures are as of the close on October 22, 2026. The 50-day moving average sits at 1.39, while the 200-day moving average is 1.34.

Over the twelve months ended June 30, 2026, Pacific Biosciences of California, Inc. generated 139.41M in revenue and converted that into -115.00M in net income, yielding earnings per share of -0.38. EBITDA reached -101.01M, while operating income came in at -156.54M.

As of June 30, 2026, Pacific Biosciences of California, Inc. holds 207.33M in cash and equivalents against 618.07M in total debt, resulting in a net debt position of 510.59M. Total book value stands at -29.07M, with working capital of 236.18M providing operational flexibility.

Pacific Biosciences of California, Inc. produced -103.33M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -10.88M in capital expenditures, free cash flow totaled -114.21M - equivalent to -0.37 per share.

Over the twelve months ended June 30, 2026, Pacific Biosciences of California, Inc. posted a gross margin of 36.38, reflecting its pricing power and cost economics. The operating margin of -112.28 and net profit margin of -82.49 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -24.69: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.59, meaning Pacific Biosciences of California, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Pacific Biosciences of California, Inc. has an Altman Z-Score of -8.98, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.